Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Wednesday, February 26, 2020 at 3:00 p.m. ET....
Today, we will study why ChemoCentryx ( CCXI ) is a promising investment opportunity in 2020. Company overview ChemoCentryx is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune diseases, inflammatory disorders, and cancer. The major...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with this Read more ...
MOUNTAIN VIEW, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc. (NYSE: HTGC), a leader in customized financing for companies in life sciences a...
MOUNTAIN VIEW, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednesday January 15, 2020 at 1:30 p.m. PT. Th...
Shares of ChemoCentryx (NASDAQ: CCXI) have shot up significantly after the company announced positive results for a trial focusing on its leading drug candidate. With investors impressed by this piece of news and Wall Street analysts doubling down on their already optimistic ratings f...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
ChemoCentryx ( CCXI ) and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that they had achieved positive results from the phase 3 study treating patients with ANCA-associated vasculitis using the drug Avacopan. What makes these results substantial is that pati...
After management reported that its oral selective complement 5a receptor inhibitor, avacopan, successfully treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis) in phase 3 studies, ChemoCentryx (NASDAQ: CCXI) shares...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...